Pharmacological stimulation of peroxisome proliferator-activated receptor-gamma (PPAR-γ) has been recognized as a molecular switch in alleviating myocardial injury through modulating oxidative, inflammatory and apoptotic signaling pathways. This study was designed to elucidate the effect of chrysin, a novel PPAR-γ agonist and its functional interaction with TGF-β/MAPKs in isoproterenol-challenged myocardial injury in rats. Male Wistar Albino rats were either subjected to vehicle (1.5 mL/kg, p.o.) or chrysin (15–60 mg/kg, p.o.) for 28 days. Isoproterenol (85 mg/kg, s.c.) was administered to rats on 27th and 28th day to induce myocardial injury. Chrysin dose dependently improved ventricular (±LVdP/dtmax and LVEDP) and hemodynamic (SAP, MAP and DAP) dysfunction in isoproterenol-insulted rats. This beneficial effect of chrysin was well supported with increased expression of PPAR-γ and decreased expression of TGF-β as evidenced by western blotting and immunohistochemistry analysis. Moreover, downstream signaling pathway of TGF-β viz. P-ERK½/ERK½ activation and P-JNK/JNK, P-p38/p38 and MMP-2 inhibition were also observed. Chrysin also attenuated NF-κBp65 and IKK-β expressions, TNF-α level and TUNEL positivity thereby validating its anti-inflammatory and anti-apoptotic properties. Additionally, chrysin in a dose dependent fashion improved NO level, redox status of the myocardium (GSH and MDA levels and SOD, GSHPx and CAT activities), cardiac injury markers (CK-MB and LDH levels) and oxidative DNA damage marker (8-OHdG level) and displayed preservation of subcellular and ultrastructural components. We established that activation of PPAR-γ and inhibition of TGF-β via MAPKs dependent mechanism is critical for cardioprotective effect of chrysin.
29 November 2024 in Journal of Pharmacy and Pharmacology
Objective: Advanced glycation end products/receptor for AGEs (AGE/RAGE) signaling has a well-established role in the etiology of diabetic-related cardiovascular disorders. The purpose of the study was to elucidate the role of chrysin, a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, against ischemia/reperfusion (IR) injury in diabetic rats and its functional interaction with the AGE/RAGE signaling pathway. Methods: A single intraperitoneal injection of streptozotocin (STZ, 70 mg/kg) was administered to rats for induction of diabetes. Rats having blood glucose levels more than 300 mg/dl following a 72 hr STZ injection were classified as diabetic. PPAR-γ antagonist GW9662 (1 mg/kg, i.p.), chrysin (60 mg/kg, p.o.), or both were administered to diabetic rats for 4 weeks. On the 29th day, rats were given ischemia for 45 min and then reperfusion for 1 hr to induce myocardial infarction (MI). Key findings: Pretreatment with chrysin significantly improved hemodynamic status, ventricular functions, and cardiac injury markers in diabetic myocardium. Increased PPAR-γ/Nrf2 and decreased RAGE protein expressions were linked to this improvement. Chrysin pretreatment resulted in the upregulation of endogenous antioxidants and reduced TBARS levels. Moreover, chrysin significantly decreased inflammation and apoptosis in diabetic myocardium. Conclusion: PPAR-γ/Nrf2 co-activation by chrysin ameliorated IR-induced MI in diabetic rats, possibly via modulating AGE/RAGE signaling.
Background: Adverse drug reactions (ADRs) among pregnant women and pediatric patients are a significant public health concern. ADRs monitoring and documentation are considered essential practices to decrease the chances of ADRs and ensure the safe use of drugs. Objective: Therefore, the study was designed to evaluate the pattern of adverse drug reactions among pregnant women and pediatric patients in a tertiary care hospital. Methods: The study was conducted at Kalpana Chawla Government Medical College and Hospital, Karnal, Haryana for a period of 2 years. During this period, ADRs reported by the healthcare professionals of gynecology and pediatric department to the ADRs monitoring centre of our institute were included in the study. Results: Out of 54 total ADRs, 40 ADRs occurred among pregnant women and 14 ADRs were reported in pediatric patients. The majority of the ADRs were observed in the age group of 21-30 years (pregnant women) and 3-5 years (pediatric patients). Antibiotics were most commonly implicated in ADRs among pregnant women (60%) and pediatric patients (79%). In our study, the dermatological system was mostly affected among pregnant women and pediatric patients. Urticaria, contact dermatitis and erythematous rash were the most commonly reported ADRs among pregnant women and pediatric patients. Conclusion: Over-prescribing and irrational use of antibiotics make these vulnerable populations more susceptible to ADRs and antibiotic resistance. Therefore, there is a need to create awareness among health care professionals regarding the spontaneous reporting of ADRs for ensuring drug safety and reducing morbidity and mortality among pregnant women and pediatric patients.
Background: Around 2-3% of hospitalizations have been reported due to dermatological adverse drug reactions. Recent studies suggest that climatic variations affect the skin barrier function and extreme conditions aggravate skin disorders. Objective: The present study was designed to compare the impact of climatic variations on drug -induced skin reactions in the Northern and Eastern regions of India. Methods: We performed a one-year retrospective study to evaluate the impact of climatic variations (temperature and humidity) on drug-induced skin reactions in the Eastern (Kalyani, West Bengal) and Northern (Karnal, Haryana) regions. Drug-induced skin reactions were reported month-wise in both the Eastern and Northern regions. Temperature and humidity levels were also noted month-wise in both regions. The direct correlation between climatic variations and the number of drug reactions were assessed using Pearson's correlation and quadratic regression analysis. Results and Discussion: Overall, 99 and 81 dermatological adverse drug reactions were reported in tertiary care hospitals in the Northern and Eastern regions, respectively. During the summer season, the humidity level was found to be low in the Northern region as compared to the Eastern region. During this period, drug-induced skin reactions were reported significantly (p<0.05) more in the Northern region as compared to the Eastern region. Furthermore, quadratic regression analysis revealed that climatic variations contributed to drug reaction variability in the Northern region (68.5%) and Eastern region (23.5%). Conclusion: Therefore, the difference in the prevalence of drug-induced skin reactions may be related to the different climatic conditions among these two regions. Further studies in controlled climatic conditions should be performed for definitive correlations and to look into possible solutions.
31 August 2023 in International Journal for Research in Applied Science and Engineering Technology
Introduction: Antitubercular Drug-Induced Hepatic Dysfunction (ATDIHD) is a major challenge in treating tuberculosis, especially when using first-line drugs. Research shows that oxidative stress plays a central role in liver injury. Further, it triggers inflammatory and apoptotic pathways in liver cells. As a result, ATDIHD develops through an interplay between these pathways. Flavonoids can protect the liver from the damaging effects of TB medication by exerting antioxidant and anti-inflammatory effects. The study aimed to systematically evaluate preclinical evidence on the hepatoprotective effects of flavonoids and their mechanisms in ATDIHD. Methods: Data were collected from PubMed, Scopus, Google Scholar, and ScienceDirect to screen studies evaluating the protective effects of flavonoids against ATDIHD published up to 18 November 2025. Results: In this review, 38 studies were included. Most were preclinical, with only a few being clinical studies. Silymarin, quercetin, naringenin, and catechin showed protection against hepatic damage. Among these compounds, silymarin has been widely researched and supported by both preclinical and clinical studies. Quercetin has also been found to reduce liver toxicity by activating the Nuclear Factor Erythroid 2-related factor 2 (Nrf2) pathway and blocking Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling. Discussion: This review demonstrates that flavonoids may reduce hepatotoxicity by modulating oxidative stress, inflammatory responses, and apoptotic pathways, indicating their potential role as adjuncts to antitubercular therapy. Most of the available data, however, come from different preclinical models that use varied study designs, doses, and outcome parameters. This makes it difficult to directly apply the findings in clinical practice. Conclusion: Flavonoids show promising hepatoprotective effects in preclinical models of antitubercular drug-induced hepatic dysfunction. Further well-designed clinical studies are needed to confirm their effectiveness and safety as an add-on therapy.